Tuotekehitysputki

Kehitysputkessa olevat hoidot

Tutkimus- ja kehitysryhmiemme tavoitteena on löytää aivosairauksien taustalla olevat mekanismit. Kuljemme yhdessä kohti tavoitetta kehittää ja tarjota uusia hoitomuotoja, jotka edistävät potilaiden hoidon standardeja sekä osoittavat ne aivosairauksien alueet, joissa on suurimmat kehitystarpeet.

Hormonal / neuropeptide signaling


Projekti	Alue
Eptinezumab (anti-CGRP mAb)¹	Migraine prevention²	Filing
Vaikutusmekanismi Eptinezumab is a monoclonal immunoglobulin G1 (IgG1) antibody that binds to human calcitonin gene-related peptide (CGRP) with high specificity and high affinity for the CGRP α- and β-form. CGRP is a signaling molecule in the pathophysiology of migraine and cluster headache.
Eptinezumab (anti-CGRP mAb)¹	Cluster headache	3
Vaikutusmekanismi Eptinezumab is a monoclonal immunoglobulin G1 (IgG1) antibody that binds to human calcitonin gene-related peptide (CGRP) with high specificity and high affinity for the CGRP α- and β-form. CGRP is a signaling molecule in the pathophysiology of migraine and cluster headache. *Three phase III clinical trials, supporting registration in Asia, including China and Japan: SUNLIGHT, SUNRISE, and SUNSET trials.
Lu AG09222 (anti-PACAP mAb)³	Migraine prevention²	2
Vaikutusmekanismi Lu AG09222 is an investigational monoclonal antibody designed to bind and inhibit signaling mediated by pituitary adenylate cyclase-activating polypeptide (PACAP); a neuropeptide that is implicated in migraine pathophysiology.
Lu AG13909 (anti-ACTH mAb)⁴	Neurohormonal dysfunctions	1

Circuitry / neuronal biology


Projekti	Alue
Brexpiprazole⁵	PTSD⁶	Filing
Vaikutusmekanismi Brexpiprazole is a small molecule and a potent serotonin–dopamine activity modulator. It acts as a partial agonist at serotonin 5-HT1A and dopamine D2 receptors, and as an antagonist at serotonin 5-HT2A and noradrenaline α1B/α2C receptors. The serotonin, dopamine, and noradrenaline neurotransmitter systems may be implicated in behavioral symptoms of dementia, including agitation. *Life cycle management. In partnership with Otsuka Pharmaceutical Development & Commercialization, Inc.
Lu AF28996 (D1-D2 agonist)⁷	Parkinson's disease	1
Vaikutusmekanismi Lu AF28996 is a small molecule with agonistic properties towards D1 and D2 receptors. Concerted D1 and D2 dopamine receptor stimulation may play an important role in motor control of Parkinson’s disease patients.
MAGLi program⁸	Neurology	1
Bexicaserin (5HT2C agonist)	Developmental and epileptic encephalopathies	3

Protein aggregation, folding and clearance


Projekti	Alue	Faasi I	Faasi II	Faasi III
Amlenetug (anti α-synuclein mAb)	Synucleinopathies (MSA)				3

Neuroinflammation / Neuroimmunology


Projekti	Alue	Faasi I	Faasi II	Faasi III
Lu AG22515 (CD40L blocker)⁹	Neurology				1

CGRP: Calcitonin gene-related peptide;
Two phase III clinical trials, supporting registration in Asia, including China and Japan: SUNRISE, and SUNSET trials.
PACAP: Pituitary adenylate cyclase activating peptide;
ACTH: Adrenocorticotropic hormone. Two phase Ib trials are currently ongoing in Congenital Adrenal Hyperplasia and Cushing’s Disease. For technical reasons, the latter has been officially categorized as a Phase II trial to adhere to local requirements in Georgia;
Acts as a partial agonist at 5-HT1A and dopamine D2 receptors at similar potency, and an antagonist at 5-HT2A and noradrenaline alpha1B/2C receptors;
Post-traumatic stress disorder;
Dopamine receptor D1 and D2;
MAGLi: Monoacylglycerol lipase (“MAGlipase”) inhibitor;
Ph1b trial ongoing in TED (Thyroid Eye Disease)